188 related articles for article (PubMed ID: 26367230)
1. Risk factors and prognosis of hepatic acute GvHD after allogeneic hematopoietic cell transplantation.
Arai Y; Kanda J; Nakasone H; Kondo T; Uchida N; Fukuda T; Ohashi K; Kaida K; Iwato K; Eto T; Kanda Y; Nakamae H; Nagamura-Inoue T; Morishima Y; Hirokawa M; Atsuta Y; Murata M;
Bone Marrow Transplant; 2016 Jan; 51(1):96-102. PubMed ID: 26367230
[TBL] [Abstract][Full Text] [Related]
2. Late Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation.
Omer AK; Weisdorf DJ; Lazaryan A; Shanley R; Blazar BR; MacMillan ML; Brunstein C; Bejanyan N; Arora M
Biol Blood Marrow Transplant; 2016 May; 22(5):879-83. PubMed ID: 26743342
[TBL] [Abstract][Full Text] [Related]
3. Impact of conditioning intensity and TBI on acute GVHD after hematopoietic cell transplantation.
Nakasone H; Fukuda T; Kanda J; Mori T; Yano S; Kobayashi T; Miyamura K; Eto T; Kanamori H; Iwato K; Uchida N; Mori S; Nagamura-Inoue T; Ichinohe T; Atsuta Y; Teshima T; Murata M;
Bone Marrow Transplant; 2015 Apr; 50(4):559-65. PubMed ID: 25531281
[TBL] [Abstract][Full Text] [Related]
4. Atorvastatin for the Prophylaxis of Acute Graft-versus-Host Disease in Patients Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT).
Efebera YA; Geyer S; Andritsos L; Vasu S; Jaglowski S; Bingman A; Blum W; Klisovic R; Hofmeister CC; Benson DM; Penza S; Elder P; Cortright K; Kitzler R; Coombes K; O'Donnell L; Daneault B; Bradbury H; Zhang J; Chen X; Garman S; Ranganathan P; Yu X; Hofstetter J; Yu J; Garzon R; Scrape SR; Lozanski G; Devine SM
Biol Blood Marrow Transplant; 2016 Jan; 22(1):71-9. PubMed ID: 26256940
[TBL] [Abstract][Full Text] [Related]
5. Risk and prognostic factors for acute GVHD based on NIH consensus criteria.
Lee SE; Cho BS; Kim JH; Yoon JH; Shin SH; Yahng SA; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW
Bone Marrow Transplant; 2013 Apr; 48(4):587-92. PubMed ID: 23000645
[TBL] [Abstract][Full Text] [Related]
6. Serum albumin level predicts survival of patients with gastrointestinal acute graft-versus-host disease after allogeneic stem cell transplantation.
Ayuk F; Bussmann L; Zabelina T; Veit R; Alchalby H; Wolschke C; Lellek H; Bacher U; Zander AR; Kröger N
Ann Hematol; 2014 May; 93(5):855-61. PubMed ID: 24248672
[TBL] [Abstract][Full Text] [Related]
7. Improved Treatment-Related Mortality and Overall Survival of Patients with Grade IV Acute GVHD in the Modern Years.
El-Jawahri A; Li S; Antin JH; Spitzer TR; Armand PA; Koreth J; Nikiforow S; Ballen KK; Ho VT; Alyea EP; Dey BR; McAfee SL; Glotzbecker BE; Soiffer RJ; Cutler CS; Chen YB
Biol Blood Marrow Transplant; 2016 May; 22(5):910-8. PubMed ID: 26748160
[TBL] [Abstract][Full Text] [Related]
8. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial.
Finke J; Bethge WA; Schmoor C; Ottinger HD; Stelljes M; Zander AR; Volin L; Ruutu T; Heim DA; Schwerdtfeger R; Kolbe K; Mayer J; Maertens JA; Linkesch W; Holler E; Koza V; Bornhäuser M; Einsele H; Kolb HJ; Bertz H; Egger M; Grishina O; Socié G;
Lancet Oncol; 2009 Sep; 10(9):855-64. PubMed ID: 19695955
[TBL] [Abstract][Full Text] [Related]
9. Prophylaxis with sirolimus and tacrolimus ± antithymocyte globulin reduces the risk of acute graft-versus-host disease without an overall survival benefit following allogeneic stem cell transplantation.
Rosenbeck LL; Kiel PJ; Kalsekar I; Vargo C; Baute J; Sullivan CK; Wood L; Abdelqader S; Schwartz J; Srivastava S; Abonour R; Robertson MJ; Nelson RP; Cornetta K; Fausel CA; Farag SS
Biol Blood Marrow Transplant; 2011 Jun; 17(6):916-22. PubMed ID: 20932925
[TBL] [Abstract][Full Text] [Related]
10. Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation.
Artz AS; Wickrema A; Dinner S; Godley LA; Kocherginsky M; Odenike O; Rich ES; Stock W; Ulaszek J; Larson RA; van Besien K
Biol Blood Marrow Transplant; 2008 Nov; 14(11):1209-16. PubMed ID: 18940674
[TBL] [Abstract][Full Text] [Related]
11. Late Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation.
Arora M; Cutler CS; Jagasia MH; Pidala J; Chai X; Martin PJ; Flowers ME; Inamoto Y; Chen GL; Wood WA; Khera N; Palmer J; Duong H; Arai S; Mayer S; Pusic I; Lee SJ
Biol Blood Marrow Transplant; 2016 Mar; 22(3):449-55. PubMed ID: 26541363
[TBL] [Abstract][Full Text] [Related]
12. [Induction of aGVHD after allogeneic hematopoietic stem cell transplantation for refractory or relapsed acute leukemia].
Sun J; Meng FY; Liu QF; Xu D; Xu B; Liu XL
Ai Zheng; 2003 Dec; 22(12):1321-4. PubMed ID: 14693060
[TBL] [Abstract][Full Text] [Related]
13. Combination of low-dose mycophenolate mofetil with cyclosporine and methotrexate as GVHD prophylaxis in unrelated donor allogeneic stem cell transplantation.
Zhu X; Lai X; Luo Y; Shi J; Tan Y; Zheng W; He J; Xie W; Li L; Zhang J; Ye X; Lin M; Cai Z; Huang H
Leuk Res; 2013 Sep; 37(9):1046-51. PubMed ID: 23849987
[TBL] [Abstract][Full Text] [Related]
14. [Liver biopsy in the management of liver dysfunction after allogeneic hematopoietic stem-cell transplantation].
Chen H; Huang XJ; Liu KY; Xu LP; Wang H; Liu DH; Lu J; Lu DP
Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(43):3062-6. PubMed ID: 16324408
[TBL] [Abstract][Full Text] [Related]
15. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
Koh LP; Chen CS; Tai BC; Hwang WY; Tan LK; Ng HY; Linn YC; Koh MB; Goh YT; Tan B; Lim S; Lee YM; Tan KW; Liu TC; Ng HJ; Loh YS; Mow BM; Tan DC; Tan PH
Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257
[TBL] [Abstract][Full Text] [Related]
16. Hypoalbuminaemia segregates different prognostic subgroups within the refined standard risk acute graft-versus-host disease score.
Kharfan-Dabaja MA; Sheets K; Kumar A; Murthy HS; Nishihori T; Tsalatsanis A; Mina A; Mathews J; Ayala E; Chavez J; Perez LE; Betts BC; Anasetti C; Pidala J
Br J Haematol; 2018 Mar; 180(6):854-862. PubMed ID: 29345306
[TBL] [Abstract][Full Text] [Related]
17. Impact of pretransplant serum ferritin level on risk of invasive mold infection after allogeneic hematopoietic stem cell transplantation.
Dadwal SS; Tegtmeier B; Liu X; Frankel P; Ito J; Forman SJ; Pullarkat V
Eur J Haematol; 2015 Mar; 94(3):235-42. PubMed ID: 25082161
[TBL] [Abstract][Full Text] [Related]
18. Viral PCR positivity in stool before allogeneic hematopoietic cell transplantation is strongly associated with acute intestinal graft-versus-host disease.
van Montfrans J; Schulz L; Versluys B; de Wildt A; Wolfs T; Bierings M; Gerhardt C; Lindemans C; Wensing A; Boelens JJ
Biol Blood Marrow Transplant; 2015 Apr; 21(4):772-4. PubMed ID: 25598276
[TBL] [Abstract][Full Text] [Related]
19. A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategy.
Shore T; Harpel J; Schuster MW; Roboz GJ; Leonard JP; Coleman M; Feldman EJ; Silver RT
Biol Blood Marrow Transplant; 2006 Aug; 12(8):868-75. PubMed ID: 16864057
[TBL] [Abstract][Full Text] [Related]
20. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
